anti-VEGF | Ricerc@Sapienza

Comparison of short-term choroidal thickness and retinal morphological changes after intravitreal anti-VEGF therapy with ranibizumab or aflibercept in treatment-naive eyes

PURPOSE: To evaluate choroidal thickness (CT) and retinal morphological changes in eyes with neovascular age-related macular degeneration (nAMD) following ranibizumab or aflibercept intravitreal treatment.

VEGF inhibition alters neurotrophin signalling pathways and induces caspase-3 activation and autophagy in rabbit retina

This study sought to evaluate the prospective role exerted by vascular endothelial growth factor (VEGF) in the modulation of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) signalling pathways in the rabbit retina. To reach this aim, the anti-VEGF agents aflibercept and ranibizumab were used as a pharmacological approach to evaluate the putative consequences elicited by VEGF inhibition on neurotrophin signalling.

Evaluation of retinal ganglion cell layer in patients with macular edema treated with intravitreal anti-VEFG and corticosteroid

Purpose: The aim of the study is to detect the effect of the different intravitreal therapies (anti-VEFG drugs and corticosteroids) on the single layer of retinal ganglion cells (GCL) in patients affected by macular edema. Methods: Forty (17 males/23 females) Caucasian patients (40 eyes) affected by macular edema treated with intravitreal injections (anti-VEGF and steroids) are included. Spectralis HRA-OCT device with a specific protocol for the acquisition and evaluation of the GCL layer has been used.